Ketamine + Cognitive Training for Suicidality in the Medical Setting
Running, not enrolling · Phase 4 · Has a placebo group
Conditions studied: Suicide, Attempted
In brief
This project seeks to identify the acute and longer-term impact of a single dose of intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in the medical inpatient setting. The investigators will then test whether ketamine's rapid effects can be extended by introducing helpful information delivered by a computer-based training protocol. This work could ultimately lead to the ability to treat suicidality more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.
Key facts
- Study ID
- NCT04578938
- Run by
- Rebecca Price
- People needed
- 200
- Starts
- 2021-03-15
- Expected to finish
- 2026-12-02
- Last updated by the study team
- 2026-03-24
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants who receive ketamine will:
- be between the ages of 18 and 70 years
- be a medical inpatient referred for psychiatric consultation/liaison due to suicidality and determined by psychiatric C/L to require follow-up psychiatric care (inpatient or outpatient)
- possess a level of judgment and understanding sufficient to agree to all procedures required by the protocol and must sign an informed consent document
- be deemed an appropriate and reasonable medical candidate for intravenous ketamine by a physician authorized to prescribe medication to the patient during inpatient hospitalization
You may not qualify if…
- Presence of current/acute psychosis with significant thought disruption, mania, delirium, or dementia, or a diagnosis of developmental disorder with significant language and/or intellectual impairment
- Mini-Mental State Exam (MMSE) < 21
- Current pregnancy or breastfeeding
- Reading level <5th grade as per WRAT-3 reading subtest AND patient declines to have all questionnaire items and task instructions read aloud to them at all assessment points
- Past intolerance or hypersensitivity to ketamine or esketamine
- Patients taking St John's Wort
- Patients who have received ECT in the past 1 month prior to intake
- Patients at ongoing risk for severe substance or alcohol withdrawal related issues (e.g., delirium tremens, severe opiate withdrawal) or who present with substance-induced psychosis
- Arrested or incarcerated individuals brought in by the legal system for medical stabilization
Where it is running
- University of Pittsburgh — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.